FDA
-
-
-
-
-
-
-
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
-
-
-
-
-
-
-
MacroGenics names Eric Risser as CEO, replacing 24-year leader
-
-
-
-
-
-
-
Macrogenics (MGNX) Announces CEO Departure
-
-
-
-
-
-
-
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
-
-
-
-
-
-
-
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
-
-
-
-
-
-
-
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
-
-
-
-
-
-
-
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
-
323,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

